Healthcare systems have had to adapt to evolving challenges in recent years, and in response, the pharmaceutical and biotechnology sectors have implemented different innovative pricing and reimbursement models. Here the Life Sciences Practice team at CRA explores whether similar innovative reimbursement and contracting schemes might be developed for medical technologies and how the challenges they bring might be overcome. By Joanne Clark, Bhavesh Patel, and Mireia Cortina, CRA Life Sciences.
The availability of more innovative medical devices, increasing budget pressures, and requirements for real-world data are some factors driving the development of new and innovative contracting schemes in medtech. But several rapidly emerging challenges including pushback from payors are hindering their adoption, requiring strategic device manufacturers to consider alternative strategies related to reimbursement.